Skip to content

Dami Rebergen

Cyclomics gets the SME Instrument grant

Based on a well-balanced proposal describing further developments to strengthen their business case, Cyclomics received 50,000 EUR in funding from the European Commission, as part of the SME Instrument phase 1 program. The project proposal was put together in a collaborative effort with Catalyze, an Amsterdam-based Life Sciences consultancy company. “We are thrilled to receive this grant, as a recognition… Read More »Cyclomics gets the SME Instrument grant

Funds for clinical testing in collaboration with UMCU & NKI

In a combined effort, Cyclomics in collaboration with the University Medical Center Utrecht and the Netherlands Cancer Institute, will test their circulating tumor DNA sequencing technology for recurrence detection and treatment response monitoring in patients with advanced stage head and neck cancer. More than 90% of patient with HPV-negative head and neck cancer contain mutations in the TP53 gene. Cyclomics… Read More »Funds for clinical testing in collaboration with UMCU & NKI

Cyclomics obtains the Take-Off grant

Cyclomics and the University Medical Center Utrecht obtained 50.000 EUR in funding for further technical development and evaluation of their highly accurate mutation detection technology, which is based on proprietary DNA concatemerization technology and novel bioinformatics algorithms for mutation detection. Within the context of the Take Off grant, the Cyclomics team and researchers from the University Medical Center Utrecht will… Read More »Cyclomics obtains the Take-Off grant

Cyclomics wins the Venture Challenge

Following a successful Health Holland Venture Challenge coaching program, involving the preparation of a business plan and a slide deck, Cyclomics participated into a pitch contest in front of a jury consisting of seasoned biotech entrepreneurs and experts. After a long deliberation of the jury, the winners were announced two weeks later at the Dutch Life Sciences conference at the… Read More »Cyclomics wins the Venture Challenge